ITRM logo

Iterum Therapeutics (ITRM)

Profile

Full Name

Iterum Therapeutics plc

Ticker Symbol

ITRM

Exchange

NASDAQ

Country

Ireland

IPO

May 25, 2018

Indexes

Not included

Employees

9

Key Details

Price

$1.05(-6.25%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

-

Annual EPS

-$1.26(+53.83% YoY)

PE ratio

-

Next earnings date

May 13, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Aug 15, 24 HC Wainwright & Co.
Buy
Jun 21, 24 HC Wainwright & Co.
Buy
May 31, 24 HC Wainwright & Co.
Buy
May 14, 24 HC Wainwright & Co.
Buy
Apr 30, 24 HC Wainwright & Co.
Buy
Apr 1, 24 HC Wainwright & Co.
Buy
Mar 6, 24 HC Wainwright & Co.
Buy
Feb 7, 24 HC Wainwright & Co.
Buy
Jul 27, 21 Gabelli & Co.
Hold
Jul 26, 21 HC Wainwright & Co.
Neutral

Institutional Ownership

  • What is the ticker symbol for Iterum Therapeutics?
  • Does Iterum Therapeutics pay dividends?
  • What sector is Iterum Therapeutics in?
  • What industry is Iterum Therapeutics in?
  • What country is Iterum Therapeutics based in?
  • When did Iterum Therapeutics go public?
  • Is Iterum Therapeutics in the S&P 500?
  • Is Iterum Therapeutics in the NASDAQ 100?
  • Is Iterum Therapeutics in the Dow Jones?
  • When was Iterum Therapeutics's last earnings report?
  • When does Iterum Therapeutics report earnings?
  • Should I buy Iterum Therapeutics stock now?

What is the ticker symbol for Iterum Therapeutics?

The ticker symbol for Iterum Therapeutics is NASDAQ:ITRM

Does Iterum Therapeutics pay dividends?

No, Iterum Therapeutics does not pay dividends

What sector is Iterum Therapeutics in?

Iterum Therapeutics is in the Healthcare sector

What industry is Iterum Therapeutics in?

Iterum Therapeutics is in the Biotechnology industry

What country is Iterum Therapeutics based in?

Iterum Therapeutics is headquartered in Ireland

When did Iterum Therapeutics go public?

Iterum Therapeutics's initial public offering (IPO) was on May 25, 2018

Is Iterum Therapeutics in the S&P 500?

No, Iterum Therapeutics is not included in the S&P 500 index

Is Iterum Therapeutics in the NASDAQ 100?

No, Iterum Therapeutics is not included in the NASDAQ 100 index

Is Iterum Therapeutics in the Dow Jones?

No, Iterum Therapeutics is not included in the Dow Jones index

When was Iterum Therapeutics's last earnings report?

Iterum Therapeutics's most recent earnings report was on Feb 7, 2025

When does Iterum Therapeutics report earnings?

The next expected earnings date for Iterum Therapeutics is May 13, 2025

Should I buy Iterum Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page